1-chloro-3-methyl-3-phenylbutan-2-one | 64922-05-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-chloro-3-methyl-3-phenylbutan-2-one
• CAS: 64922-05-0
• 化学式: C₁₁H₁₃ClO
• 分子量: 196.677
• InChiKey: GQQUKXOVRPQCHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-chloro-3-methyl-3-phenylbutan-2-one 在 sodium hydroxide 、 水 、 三乙胺 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 13.33h， 生成 3-hydroxy-2-(2-phenylpropan-2-yl)-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid
  参考文献：
  名称：

  Methods and Compositions for Selectin Inhibition

  摘要：

  本教学涉及到式I的新化合物： 其中组成变量如本文所定义。本教学的化合物可以作为被称为选择素的哺乳动物粘附蛋白的拮抗剂。提供了治疗或预防选择素介导的疾病的方法，包括以治疗有效剂量给予这些化合物。

  公开号：

  US20080255192A1
• 作为产物：
  描述：

  3-甲基-3-苯基丁烷-2-酮 生成 1-chloro-3-methyl-3-phenylbutan-2-one
  参考文献：
  名称：

  REGEL, E.;BUECHEL, K. -H.;PLEMPEL, M.

  摘要：

  DOI：

文献信息

• Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury
  作者：Adrian Huang、Alessandro Moretto、Kristin Janz、Michael Lowe、Patricia W. Bedard、Steve Tam、Li Di、Valerie Clerin、Natalia Sushkova、Boris Tchernychev、Desiree H. H. Tsao、James C. Keith、Gray D. Shaw、Robert G. Schaub、Qin Wang、Neelu Kaila

  DOI：10.1021/jm9013696

  日期：2010.8.26

  Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure activity-studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.
• REGEL, E.;BUECHEL, K.;LUERSSEN, K.;FROHBERGER, P.;PAUL, V.
  作者：REGEL, E.、BUECHEL, K.、LUERSSEN, K.、FROHBERGER, P.、PAUL, V.

  DOI：——

  日期：——
• Triazolylpropenol-Derivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pflanzenwachstumsregulatoren und Fungizide
  申请人：BAYER AG

  公开号：EP0044993B1

  公开（公告）日：1985-05-29
• AMINOPYRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES CONTAINING THE SAME
  申请人：Korea Research Institute Of Chemical Technology

  公开号：EP2059503A1

  公开（公告）日：2009-05-20
• [EN] BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RECEPTEUR CANNABINOIDE CB2 BICYLCIQUE
  申请人：PHARMOS CORP

  公开号：WO2003064359A1

  公开（公告）日：2003-08-07

  The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) α-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, neuropathic and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.